Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

Autor: Conte, P., Frassoldati, A., Bisagni, G., Brandes, A. A., Donadio, M., Garrone, O., Piacentini, F., Cavanna, L., Giotta, F., Aieta, M., Gebbia, V., Molino, A., Musolino, A., Ferro, A., Maltoni, R., Danese, S., Zamagni, C., Rimanti, A., Cagossi, K., Russo, A., Pronzato, P., Giovanardi, F., Moretti, G., Lombardo, L., Schirone, A., Beano, A., Amaducci, L., Bajardi, E. A., Vicini, R., Balduzzi, S., D'Amico, R., Guarneri, Falci C, V., Giarratano, T, Mcmahon, L, De Salvo GL, Dieci, Mv, Maiorana, A, Ficarra, G, Caggia, F, Grisolia, D, Bartolini, S, Lorusso, V, Ardito, R, Tartarone, A, Vanella, P, Taverniti, C, Porpiglia, M, Spanu, Pg, Biglia, N, Andreis, D, Piancastelli, A, Fedeli, A, Parra, Hs, Gambaro, Ar, Romito, S, Malossi, A, Gori, S, Miglietta, L, Del Mastro, L, Amoroso, D, Mansutti, M, Generali, D, Prati, G, Bertolini, A, Berardi, R, Zanni, A, Cottafavi, L, Bologna, A, Naso, G, Pancotti, A, Farci, D, Zoboli, A, Silva, R, Laudadio, L, Bordonaro, R, Marenco, D, Dongiovanni, V, Baldini, E, Saggia, C, Gorzegno, G, Cariello, A, Biganzoli, L, Rampello, E.

Publikováno v: Annals of Oncology. 29:2328-2333

Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b61f781b7e9350a5669985b12e94ae5c
https://doi.org/10.1093/annonc/mdy414

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow

Autor: Camillo Almici, Manoni, L., Carlo-Stella, C., Garau, D., Cottafavi, L., Rizzoli, V.

Publikováno v: Scopus-Elsevier
Europe PubMed Central

Autologous bone marrow transplantation (ABMT) is used increasingly for the treatment of acute leukemias, lymphomas and solid tumors. Since ABMT is burdened by high risk of relapse, mafosfamide or 4-hydroperoxycyclophosphamide chemical marrow purging

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::6653834d473c16a09573025a4698ef96
https://pubmed.ncbi.nlm.nih.gov/7581136

Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide

Autor: Carlo-Stella, C., Mangoni, L., Camillo Almici, Caramatti, C., Cottafavi, L., Dotti, G. P., Rizzoli, V.

Publikováno v: Scopus-Elsevier
Europe PubMed Central

Ten adult patients with Ph-positive chronic myelogenous leukemia (CML) received autologous transplantation using marrow treated ex vivo with mafosfamide. At transplant, 7 patients were in chronic phase (5 in first, 2 in second) and 3 in accelerated p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::db33493e4821640f8d2ac32b10a3e8a3
https://pubmed.ncbi.nlm.nih.gov/7994267

Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow

Autor: Carlo-Stella, C, Mangoni, L, Almici, C, Cottafavi, L, Meloni, G, Mandelli, F, Rizzoli, V

Publikováno v: Blood; November 1992, Vol. 80 Issue: 9 p2412-2418, 7p